Quantum Cyber N.V. current report, Q2 FY2023

Business Context and Reporting Period

This Form 6-K filing is submitted by Mainz Biomed N.V. (not Quantum Cyber N.V. as indicated in metadata) for the three and six months ended June 30, 2023. The report, dated August 15, 2023, serves to make available the Company's Management's Discussion and Analysis (MD&A), unaudited financial statements, and a press release regarding its financial results for the specified periods.

Key Financial Metrics

The provided text is a cover sheet and does not contain specific numerical data. It references attached exhibits (99.1, 99.2, and 99.3) which contain the detailed financial statements and MD&A. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this filing text.

Material Changes

The filing text does not provide specific details on material changes versus prior periods. It only confirms that the Company has released its results for the three and six months ended June 30, 2023, in the attached exhibits.

Guidance, Outlook, and Risks

This specific document does not contain management commentary, guidance, outlook, or risk factors. These elements are contained within the attached Management's Discussion and Analysis (Exhibit 99.1) and the Press Release (Exhibit 99.3), which are incorporated by reference.

Investor Verification Checklist

  • Verify the correct registrant name is Mainz Biomed N.V., noting the discrepancy with the metadata provided.
  • Review Exhibit 99.1 for the detailed MD&A and specific financial performance metrics.
  • Examine Exhibit 99.2 for the unaudited financial statements to confirm revenue, expenses, and cash position.
  • Read Exhibit 99.3 (Press Release) for management's qualitative commentary on the results.
  • Confirm the incorporation of these exhibits into the Company's Registration Statement on Form F-3 (File No. 333-269091).
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.